The predictive role of BRAF mutation in response to anti-EGFR therapy remains uncertain; however, previous studies found that BRAF mutations are associated with an adverse clinical outcome, especially in advanced stage CRC [16, 19, 20]. The gene discussed is EGFR; the disease is colorectal carcinoma.